top of page

Taking a deep dive into the IgA nephropathy (IgAN) space with the CEO of Vera Therapeutics

Marshall Fordyce describes the rationale of targeting both BAFF and APRIL as a B-cell modulator for IgAN, highlights 72 week data Vera released in January, and discusses the potential path to market in this space.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page